Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban plus Aspirin and Clopidogrel in Acute Coronary Syndrome
NCT05573958Phase 4Unknown
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in acute coronary syndrome (ACS) (2 arms). Primary endpoint: Major Adverse Cardiovascular Events at 3 months. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05573958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573958.